ERBB2 and neoplasm: These results are directly reflected upon cellular phenotypes where tumor cells harboring potential molecular targets such as genomic amplification of ERBB2 against afatinib and somatic mutation of PIK3CG against PKI587, and ALK mutations against ceritinib remained susceptible to respective target compounds.